Active	Status	Sponsor type	Region	Phase	Filter
7 Active 4 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gurtner, Geoffrey C
PL-5, NCT06189638: Phase II Study to Evaluate Efficacy and Safety of AMP Peptide in Mild Infections of Diabetic Foot Ulcers	Active, not recruiting	2	90	US	Antimicrobial Peptide PL-5 Topical Spray and Placebo, AMP PL-5 and Placebo	Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., Parexel	Diabetic Foot Ulcers	04/27	12/27
NCT03855514: Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers	Recruiting	N/A	200	US	NuShield	Organogenesis	Diabetic Foot Ulcer	11/21	12/21

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gurtner, Geoffrey C
PL-5, NCT06189638: Phase II Study to Evaluate Efficacy and Safety of AMP Peptide in Mild Infections of Diabetic Foot Ulcers	Active, not recruiting	2	90	US	Antimicrobial Peptide PL-5 Topical Spray and Placebo, AMP PL-5 and Placebo	Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., Parexel	Diabetic Foot Ulcers	04/27	12/27
NCT03855514: Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers	Recruiting	N/A	200	US	NuShield	Organogenesis	Diabetic Foot Ulcer	11/21	12/21